SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
NBS1 Glu185Gln polymorphism and susceptibility to urinary system cancer: a meta-analysis.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- Investigating the association of NBN gene polymorphisms with multiple cancers through statistical meta-analysis and bioinformatics insights.Biology methods & protocols · 2026Review
- Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.Oncology reviews · 2023Article
- Article
- NBS1 rs2735383 polymorphism is associated with an increased risk of laryngeal carcinoma.BMC cancer · 2018Article
- rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.Scientific reports · 2016Article
- DNA repair system and renal cell carcinoma prognosis: under the influence of NBS1.Medical oncology (Northwood, London, England) · 2015Article
- Carriage of NBN polymorphisms and acute leukemia risk.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of studies have investigated the association between the NBS1 Glu185Gln (rs1805794, 8360 G>C) polymorphism and risk for urinary system cancer including bladder cancer, prostate cancer, and renal cell cancer; however, the findings are conflicting. We conducted a meta-analysis focusing on eight published studies with 3,542 cases and 4,210 controls to derive a more precise evaluation of the relationship between the NBS1 Glu185Gln polymorphism and urinary system cancer susceptibility. Overall, the NBS1 Glu185Gln polymorphism was significantly related to increased risk for urinary system cancer (homozygous model: odds ratio (OR)=1.23, 95 % confidence interval (95% CI)= 1.05–1.44, p=0.011; heterozygous model: OR=1.14, 95% CI=1.04–1.26, p=0.008; dominant model: OR=1.16, 95% CI=1.05–1.27, p=0.002; and Gln vs. Glu: OR=1.12, 9% CI=1.04–1.20, p=0.002) and further stratification analysis indicated an increased risk for bladder cancer (heterozygous model: OR=1.13, 95% CI=1.02–1.26, p=0.022; dominant model: OR=1.14, 95% CI=1.03–1.26, p=0.014; and Gln vs. Glu: OR=1.09, 95%CI=1.01–1.18, p=0.023) and Caucasian populations (homozygous model: OR=1.33, 95% CI=1.11–1.59, p=0.002; heterozygous model: OR=1.16, 95% CI=1.04–1.30, p=0.009; dominant model: OR=1.19, 95% CI=1.07–1.32, p=0.001; and Gln vs. Glu: OR=1.15, 95% CI=1.06–1.25, p<0.001). Despite some limitations, this meta-analysis established some solid statistical evidence for the association between NBS1 Glu185Gln polymorphism and increased risk for urinary system cancer, especially for bladder cancer, but more well-designed prospective studies are needed to further verify our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.